HomeCLINICAL TRIALS, STUDIES, REGISTRIES, DATA
CLINICAL TRIALS, STUDIES, REGISTRIES, DATA
Clinical trials, studies, data, and updates reported in Medical Device News Magazine.
Inspira Technologies Announces First in Human of HYLA Blood Sensor in Clinical Study
The HYLA Blood sensor is a non-invasive optical blood sensor, being developed using machine learning based algorithms to measure blood key parameters, continuously and in real-time during extracorporeal procedures including VV-ECMO, VA-ECMO and open-heart surgery.
Ancora Heart’s AccuCinch System Demonstrates Significant Improvement in Quality of Life, Cardiac Structure and Function in Heart Failure Patients
Dr. Hamid. “We witnessed significant and progressive reverse remodeling of the left ventricle, as well as significant and sustained improvement in quality of life and functional capacity measures. These results show promise that this innovative catheter-based therapy may help broaden options for treating patients with heart failure, and we look forward to results of the pivotal study that’s underway.”
Todd Lanman MD Announces Completion of First Lumbar Total Joint Replacement Procedure in California as Part of a Clinical Trial
Tom Lanman MD “The century-old ‘go-to’ procedure of fusing the spine should be a thing of the past. We strongly believe that at least half of fusions in the U.S. should never have been done in the first place. Every other joint in the body gets a replacement, and the spine should be no different.”
DermaSensor Unveils Study Results Demonstrating the Ability to Detect Skin Cancer with Device Granted FDA Breakthrough Designation
“It is an honor to have been selected to present data at the AAD from our two major clinical validation studies, which are two of our four studies serving as principal support for our FDA submission,” said DermaSensor’s CEO, Cody Simmons. “Having spent a decade miniaturizing and conducting studies with our spectroscopy technology, we hope to soon equip PCPs in the U.S. with our handheld, wireless device in order to improve their detection and referral of skin cancer, which is more common than all other cancers combined.”
Over 1,000 Patients Enrolled in Landmark SELUTION DeNovo Study
SELUTION DeNovo compares the treatment strategy using a novel sirolimus drug-eluting balloon [DEB SELUTION], versus a limus drug-eluting stent [DES].
AI Accurately Identifies Normal and Abnormal Chest X-rays
An AI tool that can accurately differentiate between normal and abnormal chest X-rays would greatly alleviate the heavy workload experienced by radiologists globally.
New Study Shows High Patient Satisfaction and Outcomes After Outpatient Joint Arthroplasty at Academic Medical Centers
The study, "Patient Satisfaction and Outcomes following Outpatient Joint Arthroplasty in Academic Medical Centers," presented at the 2023 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, also showed that patients had short discharge times and low readmission rates after outpatient total joint arthroplasty.
New Study Demonstrates that Running Does Not Increase Risk of Arthritis
Dr. Hartwell and his colleagues conducted the prospective cohort study, "Does Running Increase the Risk for Hip and Knee Arthritis? A Survey of 3,804 Chicago Marathon Runners," during his residency at Northwestern University Feinberg School of Medicine in Chicago.
Total Hip Arthroplasty Patients Under 65 Have Low Revision Rates at Eight Years
In the study, "Trends in Complications and Outcomes in Patients Aged 65 and Younger Undergoing Total Hip Arthroplasty: Data from the American Joint Replacement Registry," the team used the Registry's database to identify all THA procedures performed from 2012 through 2020 in patients aged 18 to 65. Exclusion criteria included patients with revision and oncologic THA cases, conversion from prior surgery and non-elective cases. The study measured primary outcomes including cumulative revision rate, 90-day readmission rate and reason for revision. In total, 5,153 patients were included in the analysis (51% female and 49% male) with an average age of 56.7 years ± 7.8 years. Mean follow up was 39.57 months.